A Phase I, Single-Dose, Randomized, Cross-Over, Relative Bioavailability, and Food Effect Study of GDC-0973 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Cobimetinib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 11 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Dec 2010 New trial record
- 06 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.